LEOPARD: Multicenter Study on the Efficacy and Safety of OCS-01 in Subjects With Uveitis Related and Post Surgical Macular Edema

Sponsor

Quan Dong Nguyen (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05608837

Collaborator

Global Ophthalmic Research Center (GORC) (Other), Oculis (Industry)

Enrollment

Arms

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

The goal of the LEOPARD clinical trial is to investigate a new kind of steroid eye drops, OCS-01.

Macular edema is a condition in which there is collection of fluid (edema) in the back of the eye (Macula) and it can lead to severe loss of vision. Among other causes, macular edema can happen because of a disease of the eye called Uveitis, and also after eye surgery. Treatment of macular edema remains a challenge as the condition may persist for several months and may lead to irreversible changes in the eye and poor vision.

In the LEOPARD study the investigators wish to see how safe is the study drug (OCS-01) and how well it works, in resolving the fluid collection in the eye in patients with Uveitis or in patients who have had eye surgery.

Participants will undergo detailed eye exam, and record their eye and medical history to see what their disease status is and if they can be included in the study based on the study criteria. If included, they will take the study drug OCS-01 in different doses for 24 weeks. During the study period, they will have regular eye exams to ensure their safety and to assess the usefulness of the study drug.

Condition or Disease	Intervention/Treatment	Phase
Uveitis Related Cystoid Macular Edema Cystoid Macular Edema, Postoperative	Drug: OCS-01	Phase 2

Detailed Description

LEOPARD is a prospective, multi-center, open label, randomized, non-controlled, study. At least 24 eligible subjects (12 with Uveitic macular edema and 12 with Post surgical macular edema) are to be enrolled in the study. There will be 5 sites and the total treatment period is 24 weeks.

The study will consist of 4 phases: Screening Phase, Loading Phase, Treatment Phase and Follow-up Phase. Subjects will receive their assigned treatments until week 04, get randomized into groups and continue their assigned treatments until week 12. Primary endpoint assessments will be performed at week 12.

From week 12 to week 24, if there is still edema as demonstrated on OCT, subjects will receive treatment based on the retreatment criteria.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

24 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Efficacy and Safety of Dexamethasone ophthaLmic Suspension Eye drOps in Uveitic and Post Surgical mAculaR eDema (The LEOPARD Study)

Anticipated Study Start Date :

Dec 1, 2022

Anticipated Primary Completion Date :

Oct 1, 2023

Anticipated Study Completion Date :

Dec 1, 2023

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Group 1 UME From baseline until week 4 all participants will receive 01 drop of OCS-01, six times a day. At week 4, participants will be randomized to receive 01 drop of OCS-01 either six times a day OR three times a day until the primary end point at week 12. Starting week 12 the treatment will be administered based on the retreatment criteria until the end of study at week 24.	Drug: OCS-01 One drop of OCS-01 eye drops, 3-6 times daily. Dosing frequency will depend on the phase of the study. Other Names: dexamethasone ophthalmic suspension eye drops
Experimental: Group 2 PSME From baseline until week 4 all participants will receive 01 drop of OCS-01, six times a day. At week 4, participants will be randomized to receive 01 drop of OCS-01, either six times a day OR three times a day until the primary end point at week 12. Starting week 12 the treatment will be administered based on the retreatment criteria until the end of study at week 24.	Drug: OCS-01 One drop of OCS-01 eye drops, 3-6 times daily. Dosing frequency will depend on the phase of the study. Other Names: dexamethasone ophthalmic suspension eye drops

Arm

Intervention/Treatment

Experimental: Group 1 UME

From baseline until week 4 all participants will receive 01 drop of OCS-01, six times a day. At week 4, participants will be randomized to receive 01 drop of OCS-01 either six times a day OR three times a day until the primary end point at week 12. Starting week 12 the treatment will be administered based on the retreatment criteria until the end of study at week 24.

Drug: OCS-01

One drop of OCS-01 eye drops, 3-6 times daily. Dosing frequency will depend on the phase of the study.

Other Names:

dexamethasone ophthalmic suspension eye drops

Experimental: Group 2 PSME

From baseline until week 4 all participants will receive 01 drop of OCS-01, six times a day. At week 4, participants will be randomized to receive 01 drop of OCS-01, either six times a day OR three times a day until the primary end point at week 12. Starting week 12 the treatment will be administered based on the retreatment criteria until the end of study at week 24.

Drug: OCS-01

One drop of OCS-01 eye drops, 3-6 times daily. Dosing frequency will depend on the phase of the study.

Other Names:

dexamethasone ophthalmic suspension eye drops

Outcome Measures

Primary Outcome Measures

Central Subfield Thickness [Week 12]
Mean change in central subfield thickness (CST) on optical coherence tomography (OCT) at week 12 compared to baseline.
Visual Acuity [Week 12]
Mean change in early treatment of diabetic retinopathy study (ETDRS) best corrected visual acuity (BCVA) letter score at week 12.

Secondary Outcome Measures

Change in visual acuity [Baseline to end of study at 24 weeks]
Mean change in ETDRS BCVA letters at weeks 2, 4, 6, 8, 12,16, 20, and 24 compared to baseline.
Improvement in visual acuity [Baseline to end of study at 24 weeks]
The percentage of subjects who gain ≥10 or ≥15 ETDRS letters at week 12 and 24 compared to baseline.
Central Subfield Thickness [Baseline to end of study at 24 weeks]
Mean change in CST as assessed by SD-OCT at weeks 2, 4, 6, 8, 12, 16, 20, and 24 compared to baseline.
Visual function and quality of life [Baseline to end of study at 24 weeks]
Improvement in quality of life as assessed by National Eye Institute Visual Function Questionnaire (NEI VFQ-25) at Week 12, and 24 compared to baseline.
Improvement in macular leakage [Baseline to end of study at 24 weeks]
Percentage of subjects showing reduction of macular leakage on fluorescein angiography (FA) at week 12 and 24 compared to baseline

Other Outcome Measures

Change in intraocular pressure from baseline [Baseline to end of study at 24 weeks]
Monitoring of intraocular pressure at every visit for subject safety
Decline in ETDRS BCVA [Week 6 to end of study at 24 weeks]
Percentage of subjects who lose ≥15 ETDRS letters or more at weeks 6, 12, and 24 compared to baseline
Adverse effects [Each visit throughout the study up to end of study at week 24]
Participants will be directly asked at every visit during the drug exposure. In addition a contact number will be provided to the subjects to call if they experience any adverse affect or if they suspect adverse effect at any time between specific visits.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Age 18 years or older.
Diagnosis of Uveitic macular edema (UME) or post-surgical macular edema (PSME).
Can provide written informed consent prior to any study procedure being performed, able and willing to follow all instructions, and attend all study visits.
UME of less than 3 years in duration or PSME of less than 1 year since diagnosis, with presence of intraretinal and/or subretinal fluid in the study eye, with CST of ≥ 320 µm by SD-OCT at baseline (as measured by the investigator employing Heidelberg Spectralis spectral domain optical coherence tomography, SD-OCT).
An ETDRS BCVA letter score ≤ 70 (Snellen 20/40) and ≥ 35 (Snellen 20/200) in the study eye at baseline (Visit 2).
A documented diagnosis of inactive uveitis (for UME) at the screening visit.
A trial of topical NSAID or topical corticosteroids (for PSME) for at least one month but less than 3 months before screening visit with documented treatment failure on SD-OCT or based on investigator's clinical evaluation.

Note: If both eyes are eligible, the eye with the worse BCVA will be selected as the study eye. If both eyes have the same BCVA, the non-dominant eye will be selected.

Exclusion Criteria:

Subjects who meet any of the following exclusion criteria will not be included in the study

Macular edema considered to be due to a cause other than UME or PSME. An eye is not considered eligible if: (1) the macular edema is considered to be related to diabetes (2) clinical exam and/or OCT suggests that vitreoretinal interface abnormalities (e.g., a taut posterior hyaloid or epiretinal membrane) are the primary cause of the macular edema, or (3) the macular edema is considered to be related to another condition such as age-related macular degeneration, retinal vein occlusion, or drug toxicity.
A decrease in BCVA due to causes other than UME or PSME (e.g., foveal atrophy, pigment abnormalities, dense subfoveal hard exudates, previous vitreoretinal surgery, central serous retinopathy, non-retinal condition, substantial cataract, macular ischemia) that are likely to decrease BCVA by 3 lines or more (i.e., cataract would be reducing acuity to 20/40 or worse if eye was otherwise normal).
Use of other ophthalmic formulations during the study. However, intraocular pressure (IOP) lowering eye drops are allowed if they become necessary due to increased IOP.
History of glaucoma and documented glaucomatous optic neuropathy or clinically significant ocular hypertension in the opinion of the investigator, involving an IOP ≥ 25 mmHg on > 3 anti-glaucoma medications in the study eye.
Any other ocular disease that could cause substantial reduction in BCVA, including retinal detachment, epiretinal membrane, vitreous hemorrhage or fibrosis involving the macula in the study eye, other retinal inflammatory or infectious diseases.
Active peri-ocular or ocular infection (e.g., blepharitis, keratitis, scleritis, or conjunctivitis).
History of infectious uveitis.
High myopia (-8 diopter or more correction) in the study eye.
Any form of diabetic retinopathy.
History of increased intraocular pressure with topical steroid therapy.
Pregnancy/Breastfeeding

For UME:

Active uveitis as determined by the presence of anterior chamber cells or vitreous cells.
Unstable (increasing) dose of immunosuppressives during 2 months prior to the baseline visit. Immunosuppressives are defined as antimetabolites (methotrexate, mycophenolate mofetil, azathioprine, cyclosporine and tacrolimus, among others) and biologics (including adalimumab, infliximab, tocilizumab, golimumab, secukinumab and rituximab, and others).
Treated with more than 2 types of immunosuppressives (excluding steroids) within 2 months prior to baseline visit.
Unstable (increasing) dose of oral prednisone for 1 month before baseline visit.
Oral prednisone therapy at dose > 10 mg daily (or equivalent) within 1 month prior to baseline visit.
History of contact lens use within 2 weeks prior to baseline or at any time during the study.